Evidence map›Paper›PMID 39260387›Full record

ArticlePlanta medica2024

In Vitro Anti-inflammatory Effects of Larch Turpentine, Turpentine Oil, Eucalyptus Oil, and Their Mixture as Contained in a Marketed Ointment.

Kurt Appel, Thorsten Rose, Christian Zimmermann, Nils Günnewich

Abstract read
In one paragraph

Article in Planta medica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kurt AppelVivaCell Biotechnology GmbH, Denzlingen, Germany.
Thorsten RoseVivaCell Biotechnology GmbH, Denzlingen, Germany.
Christian ZimmermannCesra Arzneimittel GmbH & Co. KG, Baden-Baden, Germany.
Nils GünnewichCesra Arzneimittel GmbH & Co. KG, Baden-Baden, Germany.ORCID 0000-0002-4343-9668

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An ointment containing larch turpentine, turpentine oil, and eucalyptus oil has been used for almost a century for the symptomatic treatment of mild, localized, purulent inflammations of the skin. Its clinical efficacy in the treatment of skin infections has been shown in clinical trials, but the mode of action of the active ingredients on inflammation is not known. We studied the anti-inflammatory properties of the active ingredients of the ointment and their mixture in a human monocyte cell model, in which the cells were stimulated with lipopolysaccharide and incubated with the test substances. The cytotoxic threshold of each test substance and the mixture was identified using the alamarBlue assay, and their anti-inflammatory activity was assessed by measuring the release of interleukins IL-1

Indexed as

Anti-Inflammatory AgentsLarixTurpentineChemokine CCL2CytokinesDinoprostoneEucalyptusEucalyptus OilHumansMonocytesOintmentsPlant OilsAnti-Inflammatory AgentsChemokine CCL2CytokinesDinoprostoneEucalyptus OilOintmentsPlant OilsTurpentine

Identifiers

PMID39260387
PMCPMC11614573

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.